INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 142 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,777,568 | -23.2% | 72,520 | -6.7% | 0.00% | -50.0% |
| Q2 2023 | $4,921,231 | +12.6% | 77,720 | -3.7% | 0.00% | +100.0% |
| Q1 2023 | $4,371,475 | +67.0% | 80,729 | +63.1% | 0.00% | 0.0% |
| Q4 2022 | $2,618,000 | +663.3% | 49,484 | +571.7% | 0.00% | – |
| Q3 2022 | $343,000 | -31.1% | 7,367 | -15.5% | 0.00% | – |
| Q2 2022 | $498,000 | +8.7% | 8,719 | +16.5% | 0.00% | – |
| Q1 2022 | $458,000 | +59.0% | 7,484 | -10.8% | 0.00% | – |
| Q4 2019 | $288,000 | +93.3% | 8,386 | -27.1% | 0.00% | – |
| Q2 2019 | $149,000 | -54.6% | 11,500 | +35.9% | 0.00% | – |
| Q2 2016 | $328,000 | +42.0% | 8,460 | +1.8% | 0.00% | – |
| Q1 2016 | $231,000 | -92.9% | 8,310 | -86.3% | 0.00% | -100.0% |
| Q4 2015 | $3,271,000 | +92.4% | 60,818 | +43.2% | 0.00% | +100.0% |
| Q3 2015 | $1,700,000 | +11.5% | 42,459 | -11.0% | 0.00% | 0.0% |
| Q2 2015 | $1,525,000 | – | 47,720 | +954300.0% | 0.00% | – |
| Q3 2014 | $0 | – | 5 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |